ABEO (Abeona Therapeutics) Research & Development: $26.43 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABEO Abeona Therapeutics Inc ABEO
31 GF Score
Price $6.47
! 7 Warning Signs
View Full Analysis

What is Abeona Therapeutics Research & Development?

Abeona Therapeutics ABEO +3.77% 31 Research & Development is $26.43 Mil as of Mar. 2026. GuruFocus rates ABEO with a GF Score™ of 31/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Abeona Therapeutics's Research & Development for the three months ended in Mar. 2026 was $9.56 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $26.43 Mil.

Abeona Therapeutics  (NAS:ABEO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Abeona Therapeutics Research & Development Related Terms

Abeona Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Abeona Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abeona Therapeutics Research & Development Chart

Abeona Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.73 28.97 31.09 34.36 26.81

Abeona Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.94 5.94 4.22 6.71 9.56
ABEO
31GF Score
Abeona Therapeutics Inc ABEO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abeona Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $26.43 Mil mean?
Abeona Therapeutics (ABEO) has a Research & Development of $26.43 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Abeona Therapeutics and its competitors.
Is Abeona Therapeutics' Research & Development too high?
Abeona Therapeutics' current Research & Development is $26.43 Mil. Overall, Abeona Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' Research & Development compare to RCKT and UPB?
Abeona Therapeutics' Research & Development of $26.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current Research & Development is $26.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Abeona Therapeutics (ABEO) has a current Research & Development of $26.43 Mil. The current Research & Development is $26.43 Mil. Abeona Therapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current Research & Development is $26.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abeona Therapeutics Business Description

Other Exchanges 0H7R:UKPCJ:Germany
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
31GF Score

Get the complete analysis for ABEO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.47
Price